TCG Crossover Management, LLC
13F Reported Value
ⓘ$3.5B
Holdings
49
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
TCG Crossover Management, LLC disclosed 49 positions worth $3.5B in its Form 13F-HR for Q1 2026, led by $ABVX (Abivax S.A.) at 20.6% of the equity portfolio, followed by $CGON and $TNGX. During the quarter the fund opened 11 new positions and exited 5 — including a new stake in $BCRX and a full exit from $RAPT. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from TCG Crossover Management, LLC’s Form 13F-HR filing with the SEC under CIK 1839948.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- —
Quality
$721.7M6,481,085 sh - 28.0#2,455
Quality
$248.4M3,670,206 sh - 26.9#2,488
Quality
$220.3M10,531,071 sh - —
Quality
$190.4M4,946,894 sh - —
Quality
$170.3M4,286,480 sh - 26.8
Quality
$140.7M1,676,624 sh - —
Quality
$124.4M3,248,980 sh - —
Quality
$110.7M4,457,988 sh - 37.2
Quality
$104.9M11,020,968 sh - 32.7
Quality
$98.1M1,062,049 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Abivax S.A.$ABVX | — | $721.7M | 6,481,085 |
 CG Oncology, Inc.$CGON | 28.0#2,455 | $248.4M | 3,670,206 |
 Tango Therapeutics, Inc.$TNGX | 26.9#2,488 | $220.3M | 10,531,071 |
 Cogent Biosciences, Inc.$COGT | — | $190.4M | 4,946,894 |
 Centessa Pharmaceuticals plc$CNTA | — | $170.3M | 4,286,480 |
 Dianthus Therapeutics, Inc. /DE/$DNTH | 26.8 | $140.7M | 1,676,624 |
 Tyra Biosciences, Inc.$TYRA | — | $124.4M | 3,248,980 |
 Immunovant, Inc.$IMVT | — | $110.7M | 4,457,988 |
 BIOCRYST PHARMACEUTICALS INC$BCRX | 37.2 | $104.9M | 11,020,968 |
 Mirum Pharmaceuticals, Inc.$MIRM | 32.7 | $98.1M | 1,062,049 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of TCG Crossover Management, LLC's 49 positions.
Showing top 10 of 49 holdings.
Sector Allocation
Healthcare
$3.5B
Full Holdings — TCG Crossover Management, LLC (Q1 2026)
All 49 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $ABVX | Abivax S.A. | $721.7M | 20.6% | -9% | — |
| 2 | $CGON | CG Oncology, Inc. | $248.4M | 7.1% | +0% | 28 |
| 3 | $TNGX | Tango Therapeutics, Inc. | $220.3M | 6.3% | -17% | 26.9 |
| 4 | $COGT | Cogent Biosciences, Inc. | $190.4M | 5.5% | -16% | — |
| 5 | $CNTA | Centessa Pharmaceuticals plc | $170.3M | 4.9% | +0% | — |
| 6 | $DNTH | Dianthus Therapeutics, Inc. /DE/ | $140.7M | 4.0% | +0% | 26.8 |
| 7 | $TYRA | Tyra Biosciences, Inc. | $124.4M | 3.6% | +12% | — |
| 8 | $IMVT | Immunovant, Inc. | $110.7M | 3.2% | +168% | — |
| 9 | $BCRX | BIOCRYST PHARMACEUTICALS INC | $104.9M | 3.0% | NEW | 37.2 |
| 10 | $MIRM | Mirum Pharmaceuticals, Inc. | $98.1M | 2.8% | +1612% | 32.7 |
| 11 |  $VOR | Vor Biopharma Inc. | $96.5M | 2.8% | NEW | — |
| 12 |  $SYRE | Spyre Therapeutics, Inc. | $95.9M | 2.7% | +0% | — |
| 13 |  $AMLX | Amylyx Pharmaceuticals, Inc. | $86.8M | 2.5% | +0% | — |
| 14 |  $IRON | Disc Medicine, Inc. | $85.8M | 2.5% | NEW | — |
| 15 |  $DYN | Dyne Therapeutics, Inc. | $83.7M | 2.4% | +0% | — |
| 16 |  $GLUE | Monte Rosa Therapeutics, Inc. | $76.0M | 2.2% | +0% | 18.1 |
| 17 |  $SVRA | Savara Inc | $67.5M | 1.9% | +0% | — |
| 18 |  $RVMD | Revolution Medicines, Inc. | $56.1M | 1.6% | +32% | — |
| 19 |  $KOD | Kodiak Sciences Inc. | $55.1M | 1.6% | +0% | — |
| 20 |  $LBRX | LB PHARMACEUTICALS INC | $45.3M | 1.3% | +5% | — |
| 21 |  $SRZN | Surrozen, Inc./DE | $42.9M | 1.2% | NEW | — |
| 22 |  $ADCT | ADC Therapeutics SA | $42.7M | 1.2% | +0% | 16.3 |
| 23 |  $RLAY | Relay Therapeutics, Inc. | $42.5M | 1.2% | +33% | 12.7 |
| 24 |  $FULC | Fulcrum Therapeutics, Inc. | $40.3M | 1.1% | +0% | — |
| 25 |  $BHVN | Biohaven Ltd. | $39.2M | 1.1% | +0% | — |
| 26 |  $IPSC | Century Therapeutics, Inc. | $39.0M | 1.1% | NEW | 43.5 |
| 27 |  $TECX | Tectonic Therapeutic, Inc. | $37.2M | 1.1% | NEW | — |
| 28 |  $CATX | Perspective Therapeutics, Inc. | $33.0M | 0.9% | NEW | — |
| 29 |  $XNCR | Xencor Inc | $29.6M | 0.8% | +0% | 13.1 |
| 30 |  $TRDA | Entrada Therapeutics, Inc. | $28.9M | 0.8% | +10% | 8.5 |
| 31 |  $ALXO | ALX ONCOLOGY HOLDINGS INC | $26.1M | 0.8% | NEW | — |
| 32 |  $ARVN | ARVINAS, INC. | $25.3M | 0.7% | -10% | 13.9 |
| 33 |  $JANX | Janux Therapeutics, Inc. | $24.9M | 0.7% | +0% | 24.8 |
| 34 |  $AGMB | Agomab Therapeutics NV | $21.5M | 0.6% | NEW | — |
| 35 |  $ALEC | Alector, Inc. | $21.5M | 0.6% | +0% | 8.9 |
| 36 |  $MBX | MBX Biosciences, Inc. | $19.4M | 0.6% | +0% | — |
| 37 |  $SLN | Silence Therapeutics plc | $16.0M | 0.5% | +0% | — |
| 38 |  $LQDA | Liquidia Corp | $15.2M | 0.4% | -76% | 37.4 |
| 39 |  $OCUL | OCULAR THERAPEUTIX, INC | $14.0M | 0.4% | -71% | 12.8 |
| 40 |  $AVTX | Avalo Therapeutics, Inc. | $11.0M | 0.3% | +53% | 4.6 |
| 41 |  $URGN | UroGen Pharma Ltd. | $7.3M | 0.2% | -43% | — |
| 42 |  $MNPR | Monopar Therapeutics | $7.2M | 0.2% | -7% | — |
| 43 |  $CNTX | Context Therapeutics Inc. | $7.0M | 0.2% | NEW | — |
| 44 |  $GPCR | Structure Therapeutics Inc. | $6.8M | 0.2% | -85% | — |
| 45 |  $CGEM | Cullinan Therapeutics, Inc. | $5.8M | 0.2% | NEW | — |
| 46 |  $KRRO | Korro Bio, Inc. | $4.7M | 0.1% | +0% | 5.8 |
| 47 |  $LONA | LeonaBio, Inc. | $4.7M | 0.1% | +0% | — |
| 48 |  $UPB | Upstream Bio, Inc. | $1.6M | 0.1% | -76% | 22.6 |
| 49 |  $VTGN | Vistagen Therapeutics, Inc. | $1.5M | 0.0% | +0% | — |
New Positions (11)
$BCRX BIOCRYST PHARMACEUTICALS INC$104.9M$VOR Vor Biopharma Inc.$96.5M$IRON Disc Medicine, Inc.$85.8M$SRZN Surrozen, Inc./DE$42.9M$IPSC Century Therapeutics, Inc.$39.0M$TECX Tectonic Therapeutic, Inc.$37.2M$CATX Perspective Therapeutics, Inc.$33.0M$ALXO ALX ONCOLOGY HOLDINGS INC$26.1M$AGMB Agomab Therapeutics NV$21.5M$CNTX Context Therapeutics Inc.$7.0M$CGEM Cullinan Therapeutics, Inc.$5.8M
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for TCG Crossover Management, LLC including:
Track TCG Crossover Management, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for TCG Crossover Management, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: TCG Crossover Management, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For TCG Crossover Management, LLC (SEC CIK: 1839948), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in TCG Crossover Management, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.